In this article, we will look at the 10 Best Non-Tech Stocks to Buy According to Analysts.
On June 24, Tom Lee, Head of Research at Fundstrat Global Advisors, appeared on CNBC to talk about how the semiconductor selloff is a buying opportunity, earnings growth is supporting higher stocks, and the S&P 500 has upside beyond current targets.
He talked about the note they published recently, looking at the 17 times that the semi index, SMH, had fallen 6% more in a single day. He said that this may or may not surprise viewers, but these almost always occur in the middle of a bull market. These sharp one-day drops are not a sign of a top but are actually rather buyable entry points. One month later, 80% of the time, the semi index is higher with a 12% median gain, which means that your 6% drop is more than recovered within a month. He believes this is a “buy the pullback” moment.
READ ALSO: 12 Cheap Growth Stocks to Get Rich AND 12 Best Big Tech Stocks to Buy According to Wall Street Analysts.
Lee further talked about how, in some ways, we know that these stocks are overbought because technical measures like RSI have never been more overbought. However, when you look at valuations for the market overall, it is actually cheaper today than it was six months ago. The S&P earnings have gone up almost $50 since January of this year, and so the forward P/E went from 19.4 to 18.4. He added that viewers might think the market is ahead of earnings, but it turns out that the stock market hasn’t caught up to the rise in earnings so far.
With these broader market trends in view, let’s look at the best non-tech stocks to buy according to analysts.
Our Methodology
We used the Finviz stock screener to identify the best non-tech stocks that have high analyst upside potential (atleast 30%) and then selected the top 10 stocks most popular among hedge funds as of Q1 2026, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of analyst upside.
Note: All data was recorded on June 22.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10 Best Non-Tech Stocks to Buy According to Analysts
10. HCA Healthcare, Inc. (NYSE:HCA)
Analyst Upside: 33.54%
HCA Healthcare, Inc. (NYSE:HCA) is one of the best non-tech stocks to buy according to analysts. TD Cowen cut the price target on HCA Healthcare, Inc. (NYSE:HCA) to $431 from $500 on June 22 and maintained a Buy rating on the shares. The firm told investors in a research note that it reduced the company’s 2026 and 2027 growth assumptions after its May hospital survey showed flat year-over-year revenue. It further stated that the survey commentary shows weaker surgical volumes that were partially offset by growth in medical volumes.
In a separate development, HCA Healthcare, Inc. (NYSE:HCA) and The College of Health Care Professions announced on May 27 an agreement for HCA Healthcare to acquire ownership of CHCP. CHCP provides healthcare education to more than 8,000 students per year, across 10 campuses throughout Texas and online. Management stated that the agreement highlights a shared commitment to academic quality, student success, and workforce readiness. HCA Healthcare and CHCP have been partnering for decades, primarily through clinical sites, program advisory boards, and career placement.
HCA Healthcare, Inc. (NYSE:HCA) is a health services company involved in operating hospitals, urgent care facilities, freestanding surgery centers, emergency care facilities, walk-in clinics, diagnostic and imaging centers, comprehensive rehabilitation and physical therapy centers, radiation and oncology therapy centers, and several more. The company operates general and acute care hospitals that offer medical and surgical services.
9. SLB N.V. (NYSE:SLB)
Analyst Upside: 34.17%
SLB N.V. (NYSE:SLB) is one of the best non-tech stocks to buy according to analysts. SLB N.V. (NYSE:SLB) announced on June 15 the launch of the SLB Digital Marketplace, which is a curated digital destination specialised to help energy companies rapidly discover and deploy specialized AI agents, skills, domain models, tools, data connectors, and digital applications within their existing digital environments. It further stated that the SLB Digital Marketplace “extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers, and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel”. SLB N.V. (NYSE:SLB) stated that all marketplace offerings are certified against SLB standards for security, compatibility, and interoperability before listing.
Olivier Le Peuch, chief executive officer of SLB N.V. (NYSE:SLB), stated that AI in energy is “shifting from promise to performance,” and that the “SLB Digital Marketplace is designed to accelerate that shift by creating an open ecosystem where innovation can scale, solutions can interoperate, and customers can move faster from insight to action”.
SLB N.V. (NYSE:SLB) provides energy technology and operates through the following business segments: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems.
8. Constellation Energy Corporation (NASDAQ:CEG)
Analyst Upside: 34.28%
Constellation Energy Corporation (NASDAQ:CEG) is one of the best non-tech stocks to buy according to analysts. Constellation Energy Corporation (NASDAQ:CEG) and Walmart announced on June 23 a long-term nuclear power purchase agreement for emissions-free electricity from Constellation’s Dresden Clean Energy Center in Illinois, with the agreement including around 176 MW of wholesale supply. This includes 30 MW of expanded generating capacity. Management stated that the agreement supports reliable nuclear energy in the region, adding that Walmart will purchase energy, environmental attributes, and capacity through two 15‑year terms beginning in 2029 and 2030. It will help Walmart bolster local energy infrastructure and access cleaner energy. Jim McHugh, Senior Executive Vice President and Chief Commercial Officer, Constellation Energy Corporation (NASDAQ:CEG), stated that the agreement reflects “long‑term stewardship of critical infrastructure, the communities it serves, and the energy system that powers American growth”.
Constellation Energy Corporation (NASDAQ:CEG) further reported that through uprates at the Dresden Clean Energy Center, this agreement will provide enough new power to the grid to support Walmart’s previously announced high-tech perishable distribution center, which is currently in development in Belvidere, Ill.
Constellation Energy Corporation (NASDAQ:CEG) is involved in the generation, marketing, and supply of clean electricity and renewable energy products and services. The company’s operations are divided into the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.
7. Danaher Corporation (NYSE:DHR)
Analyst Upside: 34.80%
Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported by Masimo’s next-generation smartSET™ pulse oximetry sensor platform, the new feature employs advanced pattern recognition, which analyzes continuous physiologic data, allowing clinicians to identify early signs of respiratory compromise in hospital patients receiving opioid therapy.
In a separate development, Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a little cheaper on P/E”. It added that the Masimo (MASI) transaction “confused us about DHR’s identity.”
Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
6. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Analyst Upside: 38.29%
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. It further told investors in a research note that the deal brings a significantly more commercially capable operator with deep dermatology market relationships and decades of experience selling Humira and Skyrizi behind Zumi, which is Apogee’s long-acting IL-13 antibody in atopic dermatitis, and a potential next-gen competitor to Dupixent.
In a separate development, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab is the most potent neutralizing antibody included in Inmazeb®, according to the company, and has exhibited broad activity in vitro against multiple Ebola species, including Bundibugyo.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.
While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Non-Tech Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
